The hard part is already done: the expensive phase of a major undertaking is finished, and the company is now in the col
The model's full reasoning — Q4 2022 call → NOWe need answer only YES/NO. Need analyze transcript. Need determine if management conveys recent finished heavy phase and collecting phase begun, with results still reflecting heavy phase. Transcript: TSS Q4 2022. CEO transition, new CEO. Excess costs in Q4 due to complex new customer programs in systems integration, extra labor/overtime. Expect inflated cost to continue into Q1 2023. Labor markets tight. "We are taking steps to remediate them and to not persist materially past Q1. We do expect to continue to be adjusted EBITDA positive going forward." They discuss improved supply chain, revenue growth. But Q4 bottom line suffered from operational cost overruns and executive transition. Focus on managing current business to improve profitability, investing to scale, strategic positioning. John discusses Q4 results. CEO transition costs one-time. Higher employee costs primarily systems integration. "We are executing planned changes to our labor sourcing model and training and clearly see how these costs will normalize. Costs will remain higher than normal in Q1 as these plans take effect, but should come back into alignment with revenue thereafter." Darryll: "We have short-term issues to address in order to remediate the cost issues that impacted Q4, plus we are investing in talent and capabilities to prove our ability to deliver more customer programs in volume and in complexity. Finally, we are aggressively considering our growth strategy." Then list of actions taken: implemented incentive comp, hired new operational leaders, optimizing labor force, improved customer engagement, identified talent, set annual operating goals. Then "operational improvement needed in Round Rock integration facility. This includes updates to automation systems... industrial design review... redesign process flow, allowing for scale and predictability... We are building to scale profitably in that facility, our facility of 2x to 3x over our current capabilities." Demand generation hires. "One of our top five company goals is to obtain 10% of our revenue in 2023 from new logos." "We have begun strategic planning process..." "We have a strong base of business, new energized management teams and market opportunities to attack." "I have joined TSS because I believe there is a significant opportunity to profitably grow our business.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| HUYA | HUYA Inc. | Q4 2023 | 2024-03-19 | C |
| PUMP | ProPetro Holding Corp. | Q4 2023 | 2024-02-21 | C+ |
| AKYA | Akoya Biosciences, Inc. | Q2 2023 | 2023-08-07 | C+ |
| AFL | Aflac Incorporated | Q2 2023 | 2023-08-02 | C+ |
| DAL | Delta Air Lines, Inc. | Q2 2023 | 2023-07-13 | A |
| CURV | Torrid Holdings Inc. | Q2 2022 | 2022-09-07 | D |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| OOMA | Ooma, Inc. | Q3 2022 | 2021-12-02 | B+ |
| LPTH | LightPath Technologies, Inc. | Q4 2021 | 2021-09-09 | D |
| WES | Western Midstream Partners, LP | Q3 2018 | 2018-10-31 | D |
| HTLF | Heartland Financial USA, Inc. | Q3 2017 | 2017-10-30 | B+ |
| IBTX | Independent Bank Group, Inc. | Q3 2017 | 2017-10-24 | A |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
| ARCB | ArcBest Corporation | Q4 2016 | 2017-02-08 | C |
IONS · Q1 2017 → YESThe question is about whether management conveys that the company has recently finished the expensive, uncertain, or heavy phase of a major undertaking and has now entered the collecting phase, with r...YES Management describes the heavy phase of the SPINRAZA program as concluded ("we concluded our costly Phase III program"), with R&D expenses now expected to decline as the company transitions to a multiproduct profitable organization. They note that Q1 marked the first full quarter of commercial revenues ($47 million), with royalties of 5.2 million reflecting the early stage of this new revenue stream, while the reported results still include substantial R&D revenue (102 million) and show profitability driven by the ongoing evolution toward sustained profitability. The commercial benefits are visibly beginning but remain early, with the numbers carrying the burden of the prior development effort.
PKOH · Q3 2022 → YESThe question is about whether management conveys that the company has recently finished the expensive, uncertain, or heavy phase of a major undertaking and has now entered the phase where they collect...YES Management describes the restructuring of 14 global locations as "largely completed," with the cycle finished and no significant customer attrition. They are now pivoting to focus on the balance sheet and "harvesting some of the significant cash investments" made over the last couple of years, while noting that earnings are continuing to improve sequentially in Q4 despite inflation. The reported results show positive cash flow and improved metrics, but the harvest is described as beginning, with the $60 million working capital investment expected to convert over 12-18 months, indicating the collecting phase is early and the numbers still largely reflect the prior paying phase.
AKYA · Q2 2023 → YESThe question is about whether management conveys that the company has recently finished the expensive, uncertain, or heavy phase of a major undertaking and has now entered the collecting phase, with r...YES Management describes the first phase (2021–end of 2022) as having completed its core objectives: successful launch of Fusion, portfolio development, organizational expansion, and platform enhancements. They explicitly frame the second phase as now beginning, with the reported Q2 results still carrying the burden of that prior heavy investment (high OpEx, RIF charges, gross-margin pressure) while the new phase is visibly starting to deliver through record revenue, reagent pull-through, and cost-optimization moves. The numbers lag the crossing, as the company is still pre-profitability and targeting cash-flow positivity only in 2025.